DOCSLIB.ORG

Zero Dollar Copay List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zero Dollar Copay List August 2020 Zero Dollar Copay Drug List The following drugs are available at a $0 copay under the pharmacy benefit when covered. Inclusion of a drug in this list does not imply formulary coverage. Step therapy and prior authorization may still apply. This formulary is subject to change throughout the year. Refer to the Preferred Drug List to verify coverage. Effective for all members on September 15, 2020 Brand name Generic drug name Category ACCUPRIL QUINAPRIL HCL Blood pressure/heart health ACCURETIC QUINAPRIL/HYDROCHLOROTHIAZIDE Blood pressure/heart health ACEBUTOLOL HCL ACEBUTOLOL HCL Blood pressure/heart health ACEON PERINDOPRIL ERBUMINE Blood pressure/heart health ACETAZOLAMIDE ACETAZOLAMIDE Blood pressure/heart health ACETAZOLAMIDE ACETAZOLAMIDE SODIUM Blood pressure/heart health SODIUM ADALAT CC NIFEDIPINE Blood pressure/heart health ADENOCARD ADENOSINE Blood pressure/heart health ADENOSINE ADENOSINE Blood pressure/heart health AFEDITAB CR NIFEDIPINE Blood pressure/heart health ALDACTAZIDE SPIRONOLACT/HYDROCHLOROTHIAZID Blood pressure/heart health ALDACTONE SPIRONOLACTONE Blood pressure/heart health ALPROSTADIL ALPROSTADIL Blood pressure/heart health ALTACE RAMIPRIL Blood pressure/heart health AMILORIDE HCL AMILORIDE HCL Blood pressure/heart health AMILORIDE- AMILORIDE/HYDROCHLOROTHIAZIDE Blood pressure/heart health HYDROCHLOROTHIAZIDE AMIODARONE HCL AMIODARONE HCL Blood pressure/heart health AMLODIPINE BESYLATE AMLODIPINE BESYLATE Blood pressure/heart health AMLODIPINE ESYLATE- AMLODIPINE BESYLATE/BENAZEPRIL Blood pressure/heart health BENAZEPRIL AMLODIPINE- AMLODIPINE BES/OLMESARTAN MED Blood pressure/heart health OLMESARTAN AMLODIPINE- AMLODIPINE BESYLATE/VALSARTAN Blood pressure/heart health VALSARTAN AMLODIPINE- AMLODIPINE/VALSARTAN/HCTHIAZID Blood pressure/heart health VALSARTAN-HCTZ AMTURNIDE ALISKIREN/AMLODIPIN/HCTHIAZIDE Blood pressure/heart health ATACAND CANDESARTAN CILEXETIL Blood pressure/heart health ATACAND HCT CANDESARTAN/HYDROCHLOROTHIAZID Blood pressure/heart health ATENOLOL ATENOLOL Blood pressure/heart health www.HealthyBlueSC.com BlueChoice HealthPlan is an independent licensee of the Blue Cross and Blue Shield Association. BlueChoice HealthPlan has contracted with Amerigroup Partnership Plan, LLC, an independent company, for services to support administration of Healthy Connections. To report fraud, call our confidential Fraud Hotline at 877-725-2702. You may also call the South Carolina Department of Health and Human Services Fraud Hotline at 888-364-3224 or email [email protected]. BSCPEC-1792-20 August 2020 Healthy Blue Zero Dollar Copay Drug List Page 2 of 21 ATENOLOL- ATENOLOL/CHLORTHALIDONE Blood pressure/heart health CHLORTHALIDONE AVALIDE IRBESARTAN/HYDROCHLOROTHIAZIDE Blood pressure/heart health AVAPRO IRBESARTAN Blood pressure/heart health AZOR AMLODIPINE BES/OLMESARTAN MED Blood pressure/heart health BENAZEPRIL HCL BENAZEPRIL HCL Blood pressure/heart health BENAZEPRIL- BENAZEPRIL/HYDROCHLOROTHIAZIDE Blood pressure/heart health HYDROCHLOROTHIAZIDE BENICAR OLMESARTAN MEDOXOMIL Blood pressure/heart health BENICAR HCT OLMESARTAN/HYDROCHLOROTHIAZIDE Blood pressure/heart health BETAPACE SOTALOL HCL Blood pressure/heart health BETAPACE AF SOTALOL HCL Blood pressure/heart health BETAXOLOL HCL BETAXOLOL HCL Blood pressure/heart health BIDIL ISOSORBIDE DINIT/HYDRALAZINE Blood pressure/heart health BISOPROLOL FUMARATE BISOPROLOL FUMARATE Blood pressure/heart health BISOPROLOL- BISOPROLOL/HYDROCHLOROTHIAZIDE Blood pressure/heart health HYDROCHLOROTHIAZIDE BREVIBLOC ESMOLOL HCL Blood pressure/heart health BREVIBLOC ESMOLOL IN SODIUM CHLORIDE, ISO Blood pressure/heart health BUMETANIDE BUMETANIDE Blood pressure/heart health BYSTOLIC NEBIVOLOL HCL Blood pressure/heart health BYVALSON NEBIVOLOL HCL/VALSARTAN Blood pressure/heart health CALAN VERAPAMIL HCL Blood pressure/heart health CALAN SR VERAPAMIL HCL Blood pressure/heart health CANDESARTAN CANDESARTAN CILEXETIL Blood pressure/heart health CILEXETIL CANDESARTAN- CANDESARTAN/HYDROCHLOROTHIAZID Blood pressure/heart health HYDROCHLOROTHIAZID CAPTOPRIL CAPTOPRIL Blood pressure/heart health CAPTOPRIL- CAPTOPRIL/HYDROCHLOROTHIAZIDE Blood pressure/heart health HYDROCHLOROTHIAZIDE CARDENE I.V. NICARDIPINE HCL Blood pressure/heart health CARDIZEM DILTIAZEM HCL Blood pressure/heart health CARDIZEM CD DILTIAZEM HCL Blood pressure/heart health CARDIZEM LA DILTIAZEM HCL Blood pressure/heart health CARDURA DOXAZOSIN MESYLATE Blood pressure/heart health CARDURA XL DOXAZOSIN MESYLATE Blood pressure/heart health CAROSPIR SPIRONOLACTONE Blood pressure/heart health CARTIA XT DILTIAZEM HCL Blood pressure/heart health CARVEDILOL CARVEDILOL Blood pressure/heart health CARVEDILOL ER CARVEDILOL PHOSPHATE Blood pressure/heart health CATAPRES CLONIDINE HCL Blood pressure/heart health CATAPRES-TTS 1 CLONIDINE Blood pressure/heart health CATAPRES-TTS 2 CLONIDINE Blood pressure/heart health CATAPRES-TTS 3 CLONIDINE Blood pressure/heart health CHLOROTHIAZIDE CHLOROTHIAZIDE Blood pressure/heart health CHLOROTHIAZIDE CHLOROTHIAZIDE SODIUM Blood pressure/heart health SODIUM CHLORTHALIDONE CHLORTHALIDONE Blood pressure/heart health Healthy Blue Zero Dollar Copay Drug List Page 3 of 21 CLEVIPREX CLEVIDIPINE BUTYRATE Blood pressure/heart health CLONIDINE CLONIDINE Blood pressure/heart health CLONIDINE HCL CLONIDINE HCL Blood pressure/heart health CLORPRES CLONIDINE HCL/CHLORTHALIDONE Blood pressure/heart health CORDARONE AMIODARONE HCL Blood pressure/heart health COREG CARVEDILOL Blood pressure/heart health COREG CR CARVEDILOL PHOSPHATE Blood pressure/heart health CORGARD NADOLOL Blood pressure/heart health CORLOPAM FENOLDOPAM MESYLATE Blood pressure/heart health CORVERT IBUTILIDE FUMARATE Blood pressure/heart health CORZIDE NADOLOL/BENDROFLUMETHIAZIDE Blood pressure/heart health COZAAR LOSARTAN POTASSIUM Blood pressure/heart health DEMADEX TORSEMIDE Blood pressure/heart health DEMSER METYROSINE Blood pressure/heart health DIAMOX SEQUELS ACETAZOLAMIDE Blood pressure/heart health DIBENZYLINE PHENOXYBENZAMINE HCL Blood pressure/heart health DIGITEK DIGOXIN Blood pressure/heart health DIGOX DIGOXIN Blood pressure/heart health DIGOXIN DIGOXIN Blood pressure/heart health DILATRATE-SR ISOSORBIDE DINITRATE Blood pressure/heart health DILTIAZEM 12HR ER DILTIAZEM HCL Blood pressure/heart health DILTIAZEM 24HR CD DILTIAZEM HCL Blood pressure/heart health DILTIAZEM 24HR ER DILTIAZEM HCL Blood pressure/heart health DILTIAZEM ER DILTIAZEM HCL Blood pressure/heart health DILTIAZEM HCL DILTIAZEM HCL Blood pressure/heart health DILT-XR DILTIAZEM HCL Blood pressure/heart health DIOVAN VALSARTAN Blood pressure/heart health DIOVAN HCT VALSARTAN/HYDROCHLOROTHIAZIDE Blood pressure/heart health DISOPYRAMIDE DISOPYRAMIDE PHOSPHATE Blood pressure/heart health PHOSPHATE DIURETIC SOFTGEL PAMABROM Blood pressure/heart health DIURIL CHLOROTHIAZIDE Blood pressure/heart health DOFETILIDE DOFETILIDE Blood pressure/heart health DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE Blood pressure/heart health DUTOPROL METOPROLOL SU/HYDROCHLOROTHIAZ Blood pressure/heart health DYAZIDE TRIAMTERENE/HYDROCHLOROTHIAZID Blood pressure/heart health DYRENIUM TRIAMTERENE Blood pressure/heart health EDARBI AZILSARTAN MEDOXOMIL Blood pressure/heart health EDARBYCLOR AZILSARTAN MED/CHLORTHALIDONE Blood pressure/heart health EDECRIN ETHACRYNIC ACID Blood pressure/heart health ENALAPRIL MALEATE ENALAPRIL MALEATE Blood pressure/heart health ENALAPRILAT ENALAPRILAT DIHYDRATE Blood pressure/heart health ENALAPRIL- ENALAPRIL/HYDROCHLOROTHIAZIDE Blood pressure/heart health HYDROCHLOROTHIAZIDE EPANED ENALAPRIL MALEATE Blood pressure/heart health EPLERENONE EPLERENONE Blood pressure/heart health EPROSARTAN MESYLATE EPROSARTAN MESYLATE Blood pressure/heart health ESMOLOL HCL ESMOLOL HCL Blood pressure/heart health Healthy Blue Zero Dollar Copay Drug List Page 4 of 21 ESMOLOL HCL-WATER ESMOLOL HCL IN STERILE WATER Blood pressure/heart health ETHACRYNATE SODIUM ETHACRYNATE SODIUM Blood pressure/heart health ETHACRYNIC ACID ETHACRYNIC ACID Blood pressure/heart health EXFORGE AMLODIPINE BESYLATE/VALSARTAN Blood pressure/heart health EXFORGE HCT AMLODIPINE/VALSARTAN/HCTHIAZID Blood pressure/heart health FELODIPINE ER FELODIPINE Blood pressure/heart health FLECAINIDE ACETATE FLECAINIDE ACETATE Blood pressure/heart health FOSINOPRIL SODIUM FOSINOPRIL SODIUM Blood pressure/heart health FOSINOPRIL- FOSINOPRIL/HYDROCHLOROTHIAZIDE Blood pressure/heart health HYDROCHLOROTHIAZIDE FUROSEMIDE FUROSEMIDE Blood pressure/heart health GONITRO NITROGLYCERIN Blood pressure/heart health GUANFACINE HCL GUANFACINE HCL Blood pressure/heart health HEMANGEOL PROPRANOLOL HCL Blood pressure/heart health HYDRALAZINE HCL HYDRALAZINE HCL Blood pressure/heart health HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE Blood pressure/heart health HYZAAR LOSARTAN/HYDROCHLOROTHIAZIDE Blood pressure/heart health IBUTILIDE FUMARATE IBUTILIDE FUMARATE Blood pressure/heart health INDAPAMIDE INDAPAMIDE Blood pressure/heart health INDERAL LA PROPRANOLOL HCL Blood pressure/heart health INDERAL XL PROPRANOLOL HCL Blood pressure/heart health INNOPRAN XL PROPRANOLOL HCL Blood pressure/heart health INSPRA EPLERENONE Blood pressure/heart health IRBESARTAN IRBESARTAN Blood pressure/heart health IRBESARTAN- IRBESARTAN/HYDROCHLOROTHIAZIDE Blood pressure/heart health HYDROCHLOROTHIAZIDE ISOCHRON ISOSORBIDE DINITRATE Blood pressure/heart health ISORDIL ISOSORBIDE DINITRATE Blood pressure/heart health ISORDIL TITRADOSE ISOSORBIDE DINITRATE Blood pressure/heart health ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE
Load more

Recommended publications
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Supplementary Tables, Figures and Other Documents
    Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients David Niedrig1,2, Ali Rahmany1,3, Kai Heib4, Karl-Dietrich Hatz4, Katja Ludin5, Andrea M. Burden3, Markus Béchir6, Andreas Serra7, Stefan Russmann1,3,7,* 1 drugsafety.ch; Zurich, Switzerland 2 Hospital Pharmacy, Clinic Hirslanden Zurich; Zurich Switzerland 3 Swiss Federal Institute of Technology Zurich (ETHZ); Zurich, Switzerland 4 INTLAB AG; Uetikon am See, Switzerland 5 Labor Risch, Molecular Genetics; Berne, Switzerland 6 Center for Internal Medicine, Clinic Hirslanden Aarau; Aarau, Switzerland 7 Institute of Internal Medicine and Nephrology, Clinic Hirslanden Zurich; Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41 (0)44 221 1003 Supplementary Tables, Figures and Other Documents Figure S1: Example of credit-card sized pharmacogenomic profile issued to patients 1 Table S2: SNPs analyzed by the 16-gene panel test Gene Allele rs number ABCB1 Haplotypes 1236-2677- rs1045642 ABCB1 3435 rs1128503 ABCB1 rs2032582 COMT Haplotypes 6269-4633- rs4633 COMT 4818-4680 rs4680 COMT rs4818 COMT rs6269 CYP1A2 *1C rs2069514 CYP1A2 *1F rs762551 CYP1A2 *1K rs12720461 CYP1A2 *7 rs56107638 CYP1A2 *11 rs72547513 CYP2B6 *6 rs3745274 CYP2B6 *18 rs28399499 CYP2C19 *2 rs4244285 CYP2C19 *3 rs4986893 CYP2C19 *4 rs28399504 CYP2C19 *5 rs56337013 CYP2C19 *6 rs72552267 CYP2C19 *7 rs72558186 CYP2C19 *8 rs41291556 CYP2C19 *17 rs12248560 CYP2C9 *2 rs1799853 CYP2C9 *3 rs1057910 CYP2C9 *4 rs56165452 CYP2C9 *5 rs28371686 CYP2C9 *6 rs9332131 CYP2C9
    [Show full text]
  • Enhancement of Hepatocarcinogenesis in Female Rats by Ethinyl Estradici and Mestranol but Not Estradici1
    [CANCER RESEARCH 44, 3862-3869, September 1984] Enhancement of Hepatocarcinogenesis in Female Rats by Ethinyl Estradici and Mestranol but not Estradici1 James D. Yager,2 Harold A. Campbell, Daniel S. Longnecker, B. D. Roebuck, and Mary C. Benoit Departments ölAnatomy [J. D. Y.¡,Pathology [D. S. L], Pharmacology and Toxicology [B. D. R.¡,and Medicine [M. C. B.], Dartmouth Medical School, Hanover, New Hampshire 03756, and McArdle Laboratory tor Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706 [H. A. C.] ABSTRACT In experimental studies in animals, results have been obtained which suggest that synthetic estrogen treatment following car The effect of dietary exposure to synthetic estrogens on cinogen exposure (initiation) can enhance hepatic neoplasia. hepatocarcinogenesis was evaluated. Diethylnitrosamine-initi- Taper (32) was the first investigator to demonstrate that 2 ated and 0.85% NaCI solution-treated noninitiated female synthetic steroids used in oral contraceptive preparations in Sprague-Dawley rats were transferred to semisynthetic diets Europe, estradiol 17-phenylpropionate and estradiol benzoate, containing mestranol (0, 0.1, or 0.5 ppm), ethinyl estradiol (0.5 enhanced hepatocarcinogenesis in castrated female rats previ ppm), estradiol (0.6 ppm), or mestranol plus 0-methasone (0.5 ously initiated with A/-nitrosomorpholine In the United States, 2 and 0.2 ppm, respectively). 7-Glutamyl transferase (GGT>posi- synthetic estrogens, mestranol (170-ethinyl estradiol 3-methyl tive transections and hematoxylin and eosin-detectable nodules ether) and EE, are widely used in oral contraceptive preparations. and carcinomas were scored at 9 and 12 months. Quantitative We reported that, in intact, DEN-initiatedfemale Sprague-Dawley stereological calculations were performed to determine GGT rats, mestranol alone and together with norethynodrel enhanced lesion number and size.
    [Show full text]
  • A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
    Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies.
    [Show full text]
  • Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes
    Loyola University Chicago Loyola eCommons Master's Theses Theses and Dissertations 1974 Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes John N. Haan Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_theses Part of the Physiology Commons Recommended Citation Haan, John N., "Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes" (1974). Master's Theses. 2756. https://ecommons.luc.edu/luc_theses/2756 This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1974 John N. Haan EFFECTS OF DIETHYLSTILBESTROL, NORETHINDRONE, AND MESTRANOL ON SELECTED MICROBES by John N. Haan A Thesis Submitted to the Faculty of the Graduate School of Loyola University of Chicago in Partial Fulfillment of the Requirements for the Degree of Master of Science November 1974 TABLE OF CONTENTS ,.' I. Introduction and Review of the Literature ................... 1 'II. Materials and Methods....................................... 7 III. Results· ..................................................... 13 A. Effects of Ethanol on the Microbes Studied .............. 13 1. Growth Studies ...................................... 13 B. Effects of Norethindrone
    [Show full text]
  • Table E-46. Therapies Used in Trials Comparing Hormone with Placebo Ar Est Study N Rxcat Dose Route Generic Trade M Dose Martin 1971 1 56 Plac Oral
    Table E-46. Therapies used in trials comparing hormone with placebo Ar Est Study N RxCat Dose Route Generic Trade m Dose Martin 1971 1 56 Plac Oral Standar 2 53 EP seq 0.025 mg E + 1 mg P Oral mestranol + norethindrone d 3 56 EP seq 0.05 mg E + 1 mg P Oral mestranol + norethindrone High Campbell 1 68 Plac Oral 1977 2 68 Est 1.25 mg Oral conjugated equine estrogens Premarin High Baumgardner 1 42 Plac Oral 1978 2 42 Est 0.1 mg Oral quinestrol Estrovis Low Standar 3 35 Est 0.2 mg Oral quinestrol Estrovis d 4 37 Est 1.25 mg Oral conjugated estrogen Premarin High E-65 Ar Est Study N RxCat Dose Route Generic Trade m Dose Coope 1981 1 26 Plac Oral UltraLo 2 29 Est 0.3mg Oral piperazine estrone sulphate w Jensen 1983 1 90 Plac Oral estradiol + estriol + 2 41 EP seq 4 mg E + 1 mg P Oral Trisequens Forte High norethisterone acetate Foidart 1991 1 53 Plac VagPes Ortho-Gynest- 2 56 Est 1 mg VagPes estriol Low Depot Eriksen 1992 1 79 Plac VagTab 2 75 Est 0.025 mg VagTab estradiol Vagifem Low Wiklund 1993 11 1 Plac Patch 1 11 Standar 2 Est 0.05 mg Patch estradiol 2 d Derman 1995 1 42 Plac Oral Standar 2 40 EP seq 2 mg E + 1 mg P Oral estradiol + norethindrone acetate Trisequens d Saletu 1995 1 32 Plac Patch Standar 2 32 Est 0.05 mg Patch estradiol Estraderm d Good 1996 1 91 Plac Patch Standar 2 88 Est 0.05 mg Patch estradiol Alora d 3 94 Est 0.10 mg Patch estradiol Alora High Speroff (Study 1) 1 54 Plac Patch 1996 UltraLo 2 54 Est 0.02 mg Patch estradiol FemPatch w E-66 Ar Est Study N RxCat Dose Route Generic Trade m Dose Chung 1996 1 40 Plac Oral Standar
    [Show full text]
  • Estrogen, Progesterone and Contraceptives
    Estrogen, Progesterone and Contraceptives BY: DR MEHERUNISA CIMS ASSOCIATE PROFESSOR ESTROGEN Actions • Female reproductive system: 1. Growth and development • CNS: 1. Feedback inhibition of gonadotropin (LH/FSH) secretion. 2. stimulation of CTZ to cause nausea and vomiting. • BLOOD: 1. Increased predisposition to deep vein thrombosis and pulmonary embolism due to increased synthesis of factor VII, VIII, IX and X and decreased production of antithrombin III by the liver. 2. Favourable effect on lipid profile by decreasing LDL and increasing HDL. ESTROGEN • METABOLIC 1. Glucose intolerance 2. Sodium and water retention. 3. Maintain bone mass by decreasing the bone resorption. • Increased risk of gall bladder stones and cholestatic jaundice. • Can result in hepatic adenoma on prolonged use. • Vasodilation by increasing the production of NO. ESTROGEN PREPARATIONS • Natural steroidal estrogen ✓Estrone, Estradiol ( maximum), Estriol • Synthetic steroidal estrogen ✓Ethinyl estradil ✓Mestranol ✓Tibolone • Synthetic non steroidal estrogens ✓Diethylstilbesterol ✓Dienestrol Pharmacokinetics ✓Natural estrogens: orally inactive due to first pass metabolism ✓Synthetic estrogens: orally active ✓Estradiol is converted to estrone and estriol in liver/ peripheral tissue ✓Orally administered estrogen → absorbed from intestine→ enterohepatic circulation → high hepatic to peripheral ratio→ hepatic side effects Therapeutic uses • Oral contraceptive pills ( OCP) • Postmenopausal Hormone Replacement Therapy ( HRT) • No progesterone/estrogen production after
    [Show full text]
  • Combined Hormonal Contraceptive Use Among Breastfeeding Women: an Updated Systematic Review☆,☆☆ ⁎ Naomi K
    Contraception 94 (2016) 262–274 Review article Combined hormonal contraceptive use among breastfeeding women: an updated systematic review☆,☆☆ ⁎ Naomi K. Teppera, , Sharon J. Phillipsb, Nathalie Kappb,c, Mary E. Gaffieldb, Kathryn M. Curtisa aDivision of Reproductive Health, US Centers for Disease Control and Prevention, Atlanta, GA 30341 bDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland (prior affiliation for Dr. Phillips and Dr. Kapp) cCurrent affiliation: Independent reproductive health consultant, Paris, France Received 27 March 2015; revised 13 May 2015; accepted 13 May 2015 Abstract Background: Contraception is important for women who are postpartum, including those who are breastfeeding. Use of combined hormonal contraceptives (CHCs) may affect breastfeeding performance and infant health outcomes. Objective: The objective was to identify evidence examining clinical outcomes for breastfeeding and infant health among breastfeeding women using CHCs compared to nonusers. Search strategy: We searched the PubMed database for all articles published from database inception through September 30, 2014. Selection criteria: We included primary research studies that compared breastfeeding women using CHCs with breastfeeding women using nonhormonal or no contraception, or compared breastfeeding women initiating combined hormonal contraception at early versus later times postpartum. Breastfeeding outcomes of interest included duration, rate of exclusive breastfeeding and timing of supplementation.
    [Show full text]
  • For Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies
    Rapid and Sensitive Enzyme-Linked Immunosorbent Assays (ELISAs) for Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies Chatchaporn Uraipong Thesis submitted in partial fulfillment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales September, 2010 ABSTRACT Endocrine disrupting chemicals (EDCs) are chemicals that alter functions of the endocrine system and cause health effects in an intact organism, or progeny, or population, with reproductive, developmental, or carcinogenic consequences. In order to facilitate risk assessment of potential endocrine disrupting steroids that are present in ultra low concentrations in the Australian environment, there is a need to boost the analytical capacity for EDC detection. One strategy is to develop antibody-based techniques that can offer simple, cost-effective and reliable analysis with high throughput capacity and portability for real-time monitoring. This thesis describes the design and synthesis of hapten molecules, raising of specific antibodies, formatting and characterising of a series of sensitive competitive Enzyme-Linked Immunosorbent Assays (ELISAs) for 17β-estradiol (E2), 17α-ethynylestradiol (EE2), ethylestradiol-3-methyl ether (mestranol) and testosterone (T), including validation of their performance as fast and effective water monitoring tools. Application of the developed assays to investigate the levels of the target EDCs in bodies of water and efficiency of water treatment plants in urban and rural areas in New South Wales, Australia, is also discussed. 17α-Ethynylestradiol and related synthetic estrogens, are active ingredients of contraceptive pills and hormone therapy, and have been identified as potent EDCs (Warner and Jenkins, 2007).
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Supplemental Figure
    ● Agonist ● Antagonist ● Interference AR AUC 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 17beta−Trenbolone 5alpha−Dihydrotestosterone 17−Methyltestosterone Testosterone propionate Norethindrone Norgestrel GSK232420A 4−Androstene−3,17−dione Progesterone 17beta−Estradiol Mifepristone 17alpha−Ethinylestradiol Hydroxyflutamide 17alpha−Hydroxyprogesterone Corticosterone Nilutamide Basic Blue 7 Triphenyltin hydroxide Bicalutamide Tributyltin benzoate 17alpha−Estradiol Gentian Violet Equilin Zinc pyrithione Triticonazole Fenitrothion Mestranol Tributyltin methacrylate 2,2−Bis(4−hydroxyphenyl)−1,1,1 Dibutyltin dichloride Flutamide Methyltrioctylammonium chlorid Rhodamine 6G Tributyltetradecylphosphonium Emamectin benzoate Phenylmercuric acetate Cyproterone acetate Chlorothalonil 9−Phenanthrol 2,2',4,4'−Tetrahydroxybenzophe Melengestrol acetate Dehydroepiandrosterone 1−Chloro−2,4−dinitrobenzene SSR240612 Methylbenzethonium chloride Vinclozolin Tetraconazole Ziram Didecyldimethylammonium chlori Econazole nitrate Myristyltrimethylammonium chlo Clorophene Abamectin Octyl gallate 2−Chloro−4−phenylphenol Bisphenol A Propanil Dexamethasone sodium phosphate meso−Hexestrol Dichlorophen Hydroxyprogesterone caproate SSR241586 Bisphenol AF Prednisone Dichlone Reserpine Chlorobenzilate Diethylstilbestrol 3−Hydroxyfluorene Procymidone 4−Cumylphenol 4−Hydroxytamoxifen Napropamide PharmaGSID_48519 Clomiphene citrate (1:1) Chlorhexidine diacetate Tebuconazole Imazalil Dinocap PharmaGSID_48513 Linuron Prochloraz Zoxamide TDCPP Captan 3,3'−Dimethoxybenzidine dihydr 4−Phenylphenol
    [Show full text]
  • Toxicological Summary for Mestranol (PDF)
    Health Based Guidance for Water Health Risk Assessment Unit, Environmental Health Division 651-201-4899 Web Publication Date: May 2016 Expiration Date: May 2021 Toxicological Summary for: Mestranol CAS: 72-33-3 Synonyms: 3-Methoxy-19-nor-17α-pregna-1,3,5(10)-trien-20-yn-17-ol; (17alpha)-3-Methoxy-19- norpregna-1,3,5(10)-trien-20-yn-17-ol; Ethinylestradiol 3-methyl ether; 17alpha- Ethinylestradiol 3-methyl ether, EEME, MeEE Mestranol (MeEE) is the 3-methyl ether of 17α-ethinylestradiol (EE2). MeEE is not initially biologically active as a contraceptive hormone but it is rapidly demethylated in the liver to form the biologically active EE2. A dose of 50 µg of MeEE is considered to be bioequivalent to 35 µg of EE2 as a result of a 70% conversion efficiency in the liver (e.g., 35 µg/0.70 = 50 µg) (Brody et al. 1989). The relative bioequivalence is the basis for the different contraceptive dose levels for MeEE and EE2 used to achieve the same effect in adult humans. HBVs are available for 17α-ethinylestradiol (EE2). The Minnesota Department of Health (MDH) recommends adjusting the reference doses (RfDs) derived for EE2 by a factor of 0.7 to account for relative bioequivalence and then deriving Risk Assessment Advice (RAAs) for MeEE based on the adjusted RfDs. The following are MeEE RfDs, based on RfDs for EE2 adjusted for relative bioequivalence according to the following equation: RfDMeEE = RfDEE2/0.7 Acute RfDMeEE = Not derived. Insufficient data. -7 -7 Short-term RfDMeEE = Short-term RfDEE2/0.7 = 1.7 x 10 /0.7 = 2.4 x 10 mg/kg-d -8 -8 Subchronic RfDMeEE = Subchronic RfDEE2/0.7 = 1.4 x 10 /0.7 = 2.0 x 10 mg/kg-d -8 -8 Chronic RfDMeEE = Chronic RfDEE2/0.7 = 1.4 x 10 /0.7 = 2.0 x 10 mg/kg-d The following recommendation represents Risk Assessment Advice (RAA) for mestranol using adjusted RfDs and the same duration-based algorithms applied to derive 17α-ethinylestradiol HBVs: Acute nRAAMeEE = Not derived.
    [Show full text]